National News

AtriCure Names Two Industry Veterans to Board of Directors

12.04.2019
MASON, Ohio --(BUSINESS WIRE)--Dec. 4, 2019-- AtriCure, Inc. (Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors. Ms.

Read More

AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference

11.12.2019
MASON, Ohio --(BUSINESS WIRE)--Nov. 12, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31 st Annual

Read More

AtriCure Reports Third Quarter 2019 Financial Results

10.30.2019
Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year MASON, Ohio --(BUSINESS WIRE)--Oct. 30, 2019-- AtriCure, Inc.

Read More

AtriCure to Participate in Upcoming Investor Conferences

10.21.2019
MASON, Ohio --(BUSINESS WIRE)--Oct. 21, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences.

Read More

AtriCure to Announce Third Quarter 2019 Financial Results

10.08.2019
  MASON, Ohio --(BUSINESS WIRE)--Oct. 8, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019

Read More

AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices

08.27.2019
Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage MASON, Ohio --(BUSINESS WIRE)--Aug. 27, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA)

Read More

AtriCure to Participate at the Morgan Stanley 17th Annual Global Healthcare Conference

08.26.2019
MASON, Ohio --(BUSINESS WIRE)--Aug. 26, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Morgan Stanley 17 th Annual Global

Read More

AtriCure Completes Acquisition of SentreHEART

08.13.2019
MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.

Read More

AtriCure Enters Into Definitive Agreement to Acquire SentreHEART

08.12.2019
Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12 th at 8:30am ET MASON, Ohio --(BUSINESS WIRE)--Aug. 12, 2019-- AtriCure, Inc.

Read More

AtriCure Reports Second Quarter 2019 Financial Results

07.30.2019
Worldwide revenue of $58.9 million – an increase of 13.7% year over year U.S. revenue of $47.2 million – an increase of 15.5% year over year International revenue of $11.7 million – an increase of 7.0% year over year MASON, Ohio --(BUSINESS WIRE)--Jul. 30, 2019-- AtriCure, Inc.

Read More

International News

AtriCure Completes Acquisition of SentreHEART

08.13.2019
MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.

Read More

AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial

08.28.2018
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio --(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc.

Read More

AtriCure and Baheal Group Establish Partnership and China Distribution Agreement

06.05.2018
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes...

Read More

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide

04.25.2017
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it

Read More

AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial

03.14.2017
MASON, Ohio --(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the

Read More

AtriCure Announces Approval for the cryoICE™ Platform in Japan

11.01.2016
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio --(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today

Read More

AtriCure Receives CE Mark for the AtriClip® PRO2 Device

06.29.2016
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio --(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in

Read More

AtriCure Announces Approval for the AtriClip in Japan

01.19.2016
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio --(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA)

Read More

In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe

10.01.2013
AMSTERDAM, Netherlands --(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. ( Nasdaq: ATRC ), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program

Read More

Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery

06.18.2013
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE --(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s

Read More